David Bond on Muck Rack

David Bond

As seen in: LinkedIn, G1 Globo, IMDb, Medium, MSN, BBC, BBC Sport, Financial Times, MSN UK, Nature and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with David

Contact David, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The Unsung Hero of Every Long Ride: Understanding the Motorcycle Windshield

|
By David Bond
| SPEEDLUX
Ask most seasoned riders about the upgrades that genuinely transformed their riding experience, and somewhere near the top of the list — often surprising to newer enthusiasts — you’ll find the motorcycle windshield. It’s not like a new exhaust roaring. It’s not as attention-grabbing as custom bodywork. However, remove it from a long-distance touring bike, and you’ll notice its absence after about 10 minutes out on the highway.
Open in Who Shared Issue with article?

Auto Insurance Checklist for Premium Car Owners in Dubai

|
By David Bond
| SPEEDLUX
People have different expectations when it comes to driving a high-end car in Dubai. While performance, comfort, and design are all important, it’s also critical that the car remain protected while parked, in use, and being taken to a repair shop. Insurance isn’t just a duty, but a necessity, especially with traffic jams, long highway trips, and sometimes harsh weather.
Open in Who Shared Issue with article?

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy

|
By Yucai Wang, Melissa Larson, Steven Hwang, Diego Villa, Laveniya Kugathasan, Anita Kumar Verified, Ashlee Joseph, Taylor Brooks, Brian Hill, David Bond, Kami J. Maddocks, Alexey B. Danilov, Jia Ruan, Imran Nizamuddin, Brad S. Kahl, Natalie Grover Verified, Georgios Pongas, Izidore S. Lossos, Evguenia Ouchveridze, Aung M. Tun, Firas Baidoun, Muhamad Alhaj Moustafa, Zoey Harris, Javier Muñoz, Philip Young, Craig Portell, Patrick M Reagan, Christine Ryan, Reid W. Merryman, Arash Velayati, Drew Gerber, Preetesh Jain, Michael Wang, Eric Mou, Lauren G. Banaszak, Priyanka A. Pophali, Anthony Stack, Marcus Messmer, Mayur Narkhede, Amitkumar Mehta, Nilanjan Ghosh, Rahul S Bhansali, Stefan K. Barta, Manali K. Kamdar, Jacob L. Anna, Reem Karmali, Matthew J. Maurer, James R. Cerhan, Jonathon Cohen, Peter Martin, Christine Argao, Nazneen B. Khan, I. Brian Greenwell, Sabarish R. Ayyappan, Tamara K. Moyo, Alexander V. Stanisic
| Nature Verified
Abstract Addition of Bruton’s tyrosine kinase inhibitor (BTKi) to first-line (1 L) bendamustine-rituximab (BR) improved progression-free survival (PFS) in patients with mantle cell lymphoma (MCL) in the SHINE and ECHO trials. We investigated whether sequential treatment with 1 L BR and second-line (2 L) BTKi can result in similar cumulative PFS compared to BR-BTKi combination therapy, using a multicenter cohort of 755 patients treated with 1 L BR between 2014 and 2020.
Open in Who Shared Issue with article?
See all 1,429 licensed articles (2,242 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified